Antibody Therapeutics (Viral Targets)
Emerging Viral Infections
Pre-clinicalActive Discovery & Engineering
Key Facts
Indication
Emerging Viral Infections
Phase
Pre-clinical
Status
Active Discovery & Engineering
Company
About AbVacc
AbVacc is a private biotechnology company leveraging advanced protein engineering and immunology to create novel vaccines and antibody therapeutics against infectious diseases. Operating since 2008 in the BioCapital region of Maryland, the company's platform is designed to address the significant health and economic threats posed by emerging viral and bacterial targets, as highlighted by the COVID-19 pandemic. Their approach combines intelligent immunogen design with sophisticated antibody discovery to develop broad-spectrum protective solutions. The company brings together expertise in vaccinology, virology, bacteriology, and product development to advance its pipeline.
View full company profile